

CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xi</i>
1. Catalytic Mechanisms and Regulation of Protein Kinases	1
Zhihong Wang and Philip A. Cole	
1. Introduction	1
2. Kinetic Mechanism	2
3. Chemical Mechanism of Kinase Phosphoryl Transfer	4
4. Applications of Mechanistic Studies in Understanding Kinase Function and Regulation	9
5. Summary and Outlook	16
References	17
2. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs	23
Qi Wang, Julie A. Zorn, and John Kuriyan	
1. Introduction	24
2. Kinase Structure and Catalytic Mechanism	26
3. Staurosporine: A Promiscuous ATP-Competitive Inhibitor	31
4. BCR-Abl Inhibitors	33
5. Tofacitinib (Xeljanz™) Binds to a "DFG-in" Conformation of Janus Kinase	41
6. Inhibition of Receptor Tyrosine Kinases	42
7. Vemurafenib (Zelboraf™) Binds to A "DFG-in" Conformation in the Ser/Thr Kinase RAF	53
8. Inhibitors That Occupy Pockets Other Than the ATP-Binding Site	55
9. Summary	58
Acknowledgments	58
References	59
3. Fragment-Based Approaches to the Discovery of Kinase Inhibitors	69
Paul N. Mortenson, Valerio Berdini, and Marc O'Reilly	
1. Introduction	70
2. Fragment-Based Drug Discovery	72
3. Identifying Fragment Hits	78

4. From Fragments to Leads	80
5. Alternative Inhibition Strategies	83
6. Summary	86
Acknowledgments	88
References	88
4. Targeting Protein Kinases with Selective and Semipromiscuous Covalent Inhibitors	93
Rand M. Miller and Jack Taunton	
1. Introduction	94
2. Design of Irreversible Cysteine-Targeted Kinase Inhibitors	95
3. Targeting Noncatalytic Cysteines with Reversible Covalent Inhibitors	104
4. Semipromiscuous Covalent Inhibitors as Chemoproteomic Probes	109
5. Conclusions and Future Directions	113
References	114
5. The Resistance Tetrad: Amino Acid Hotspots for Kinome-Wide Exploitation of Drug-Resistant Protein Kinase Alleles	117
Fiona P. Bailey, Veselin I. Andreev, and Patrick A. Eyers	
1. Introduction	118
2. Protein Kinases and Kinase Inhibitors	119
3. Protein Kinase Inhibitors	119
4. Screening Approaches to Decipher Protein Kinase-Inhibitor Specificity	122
5. Random and Directed Mutagenesis Approaches Reveal Common Resistance Mechanisms	124
6. A General Procedure for Directed (Nonrandom) Mutagenesis of dsDNA Plasmids	126
7. The Resistance Tetrad Position 0: The Gatekeeper Residue	127
8. SB203580: A Paradigm for Gatekeeper-Mediated Drug Resistance from Test Tube to Mouse	129
9. Expanding the Resistance Tetrad: +2 (Hydrophobic) and +6/+7 Specificity Surfaces in Kinases	130
10. The Resistance Tetrad is a Selectivity Filter Applicable for Kinome-Wide Drug-Resistance Studies	131
11. Engineering and Analysis of Logically Designed Drug-Resistance Mutations	132
12. Analysis of Inhibitor Resistance Toward WT and DR Mutants <i>In Vitro</i>	134

13. Oncogenic Gatekeeper Mutations: Unanticipated Mechanisms of Gatekeeper Resistance Merit Biochemical Scrutiny of DR Mutants	135
14. Evaluation of Catalytic Behavior and K_M [ATP] Value for WT and DR Kinase Mutants <i>In Vitro</i>	136
15. Intact Cell Systems for Analyzing Drug Resistance and Target Validation	137
16. Generation of Stable, Isogenic Cell Lines Expressing Tetracycline-Inducible Kinases	137
17. Analysis of Kinase Drug Resistance Toward a Cytotoxic Inhibitor: Cell Growth Assay Based on Colony Formation	139
18. Conclusions	139
References	140
6. FLiK: A Direct-Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations	147
Jeffrey R. Simard and Daniel Rauh	
1. Introduction	148
2. Design and Preparation of Kinases for FLiK	152
3. Labeling of p38 α MAP Kinase with Acrylodan	155
4. Assay Characterization and Validation	156
5. HTS with FLiK	164
6. Summary	169
Acknowledgments	170
References	170
7. Discovery of Allosteric Bcr-Abl Inhibitors from Phenotypic Screen to Clinical Candidate	173
Nathanael S. Gray and Dorian Fabbro	
1. Development of ATP-Site-Directed Inhibitors of BCR-ABL for the Treatment of CML	174
2. Discovery and Characterization of Non-ATP-Site-Directed BCR-ABL Inhibitors	176
3. Characterization of the Binding of the Non-ATP-Site-Directed BCR-ABL Inhibitor GNF-2	179
4. Therapeutic Potential of First-Generation myr-Pocket Binders	183
5. Combinations of Second-Generation ATP-Site Inhibitors with Second-Generation myr-Pocket Ligands	185
Acknowledgments	186
References	186

8. The Logic and Design of Analog-Sensitive Kinases and Their Small Molecule Inhibitors	189
Michael S. Lopez, Joseph I. Kliegman, and Kevan M. Shokat	
1. Introduction	190
2. Constructing AS Kinases	193
3. AS Kinase Inhibitors	197
4. AS Kinases in Cells	207
5. AS Kinases in Living Multicellular Organisms	209
6. Summary	210
References	211
<i>Author Index</i>	215
<i>Subject Index</i>	235